DENHANBO
LIVE

Serial Number

79366767

Owner

Novartis AG

Filing Date

Feb 22, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DENHANBO Trademark

Serial Number: 79366767 • Registration: 7166573

DENHANBO is a trademark filed by Novartis AG on February 22, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Novartis AG (16 trademarks)

CH-4002 Basel

Entity Type: 03

Sandoz AG (9 trademarks)

Viaduktstrasse 3

Entity Type: 03

Trademark Details

Filing Date

February 22, 2023

Registration Date

September 19, 2023

Published for Opposition

July 4, 2023

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Sep 3, 2026 NREP
CHANGE OF OWNER RECEIVED FROM IB
Jan 19, 2024 CHLD
NOTIFICATION PROCESSED BY IB
Nov 20, 2023 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Oct 20, 2023 FICS
FINAL DISPOSITION PROCESSED
Oct 20, 2023 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Oct 19, 2023 GPAR
REGISTERED-PRINCIPAL REGISTER
Sep 19, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Jul 11, 2023 GPNX
PUBLISHED FOR OPPOSITION
Jul 4, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 21, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 21, 2023 OP2R
NOTICE OF PUBLICATION
Jun 14, 2023 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
May 30, 2023 CNSA
ASSIGNED TO EXAMINER
May 17, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 18, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 12, 2023 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 11, 2023 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 6, 2023 REPR